Fulcrum Therapeutics to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Fulcrum Therapeutics (Nasdaq: FULC) announced its participation in two virtual investor conferences. The BTIG Virtual Biotechnology Conference 2020 is scheduled for August 11, 2020, at 1:00 p.m. ET, while the Canaccord Genuity 40th Annual Growth Conference will take place on August 13, 2020, at 1:30 p.m. ET. Interested investors can access live audio webcasts through the Investor Relations section of the Fulcrum website. The company focuses on treating rare genetic diseases and is advancing several clinical programs, including treatments for muscular dystrophy and sickle cell disease.

CAMBRIDGE, Mass., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that management will participate in the following virtual investor conferences:

• BTIG Virtual Biotechnology Conference 2020
  Tuesday, August 11, 2020 at 1:00 p.m. ET
  
  
• Canaccord Genuity 40^th Annual Growth Conference
  Thursday, August 13, 2020 at 1:30 p.m. ET

Live audio webcasts of the presentations will be available through the Investor Relations section of the Fulcrum website at https://ir.fulcrumtx.com/events-and-presentations. Archived replays will be available on the Company’s website for 90 days after each conference.

About Fulcrum Therapeutics 
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s proprietary product engine identifies drug targets which can modulate gene expression to treat the known root cause of gene mis-expression. The company has advanced losmapimod to Phase 2 clinical development for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and is advancing losmapimod to Phase 3 for the treatment of COVID-19. Fulcrum also anticipates a regulatory filing in the second half of 2020 with FTX-6058 for the treatment of sickle cell disease. 

Please visit www.fulcrumtx.com.

Contact:
Stephanie Ascher
Stern Investor Relations, Inc.
stephanie.ascher@sternir.com
212-362-1200

FAQ

When is Fulcrum Therapeutics participating in the BTIG Virtual Biotechnology Conference 2020?

Fulcrum Therapeutics will participate in the BTIG Virtual Biotechnology Conference on August 11, 2020, at 1:00 p.m. ET.

What date will Fulcrum Therapeutics present at the Canaccord Genuity 40th Annual Growth Conference?

Fulcrum Therapeutics is scheduled to present at the Canaccord Genuity 40th Annual Growth Conference on August 13, 2020, at 1:30 p.m. ET.

Where can I watch the presentations from Fulcrum Therapeutics' investor conferences?

Live audio webcasts of Fulcrum Therapeutics' presentations will be available in the Investor Relations section of their website.

What are the main focuses of Fulcrum Therapeutics?

Fulcrum Therapeutics focuses on improving the lives of patients with genetically defined rare diseases, particularly in areas of high unmet medical need.

What clinical programs does Fulcrum Therapeutics have underway?

Fulcrum is advancing losmapimod for facioscapulohumeral muscular dystrophy and COVID-19, and plans regulatory filing for FTX-6058 for sickle cell disease in the second half of 2020.